IL1B and type 2 diabetes mellitus: With this clinical success has come a barrage of research using this anti-IL-1β antibody with much interest in its use in neonatal onset inflammation disease (Sibley et al., 2014), type II diabetes (Howard et al., 2014) and stroke (Ridker et al., 2011).